Retrospective Study to Evaluate Efficacy and Safety of Trabectedin (Yondelis) in Sarcoma Patients
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 12 Feb 2019
At a glance
- Drugs Trabectedin (Primary)
- Indications Bone cancer; Soft tissue sarcoma
- Focus Therapeutic Use
- Acronyms ReTraSarc
- 30 Oct 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.
- 30 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 19 Sep 2017 New trial record